Gilead Sciences (GILD)
151.00
-0.22 (0.15%)
Upcoming Events
Latest Headlines
Form 4 GILEAD SCIENCES, INC. For: Aug 26 Filed by: WELTERS ANTHONY
August 27, 2026 6:45 PM - SEC Filing
FDA approves Gilead's Bixlenvo HIV tablet for adults on complex regimens
August 27, 2026 5:47 PM - StreetInsider
U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
August 27, 2026 5:47 PM - BizWire
Form 144 GILEAD SCIENCES, INC. Filed by: WELTERS ANTHONY
August 26, 2026 4:17 PM - SEC Filing
Form N-PX GILEAD SCIENCES, INC. For: Jun 30
August 26, 2026 4:15 PM - SEC Filing
Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
August 26, 2026 4:05 PM - BizWire
EU approves Gilead's Trodelvy combo with Keytruda for front-line TNBC
August 24, 2026 6:31 AM - StreetInsider
European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
August 24, 2026 6:31 AM - BizWire
Form 4 GILEAD SCIENCES, INC. For: Aug 20 Filed by: Bluestone Jeffrey
August 21, 2026 7:22 PM - SEC Filing
Form 144 GILEAD SCIENCES, INC. Filed by: Bluestone Jeffrey
August 20, 2026 4:36 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Aug 17 Filed by: Dickinson Andrew D
August 18, 2026 7:06 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Aug 17 Filed by: Mercier Johanna
August 18, 2026 6:54 PM - SEC Filing
Form 144 GILEAD SCIENCES, INC. Filed by: Mercier Johanna
August 17, 2026 4:19 PM - SEC Filing
Form 144 GILEAD SCIENCES, INC. Filed by: Dickinson Andrew D
August 17, 2026 4:12 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Aug 10 Filed by: Cain Wettan Keeley M
August 11, 2026 4:51 PM - SEC Filing
Morgan Stanley tracks US drug market prescriptions for week ending July 31
August 7, 2026 12:04 PM - StreetInsider
Form S-3ASR GILEAD SCIENCES, INC.
August 6, 2026 5:04 PM - SEC Filing
Form 10-Q GILEAD SCIENCES, INC. For: Jun 30
August 6, 2026 4:19 PM - SEC Filing
Gilead Sciences (GILD) PT Raised to $123 at RBC Capital
August 5, 2026 7:48 AM - StreetInsider
CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
August 4, 2026 9:41 PM - BizWire
Form 4 GILEAD SCIENCES, INC. For: Aug 03 Filed by: O'Day Daniel Patrick
August 4, 2026 5:41 PM - SEC Filing
Gilead Sciences (GILD) Tops Q2 EPS by 56c
August 4, 2026 4:33 PM - StreetInsider
Form 8-K GILEAD SCIENCES, INC. For: Aug 04
August 4, 2026 4:04 PM - SEC Filing
Gilead Sciences Announces Second Quarter 2026 Financial Results
August 4, 2026 4:01 PM - BizWire
Gilead Sciences (GILD) call put ratio 1 call to 1.1 puts into quarter results
August 4, 2026 10:46 AM - StreetInsider
Form 144 GILEAD SCIENCES, INC. Filed by: O'Day Daniel Patrick
August 3, 2026 4:42 PM - SEC Filing
Form 13F-HR GILEAD SCIENCES, INC. For: Jun 30
August 3, 2026 4:38 PM - SEC Filing
Gilead Sciences (GILD) call put ratio 3.2 calls to 1 put into quarter results
August 3, 2026 10:53 AM - StreetInsider
Gilead Sciences (GILD) call put ratio 1.8 calls to 1 put into quarter results
August 3, 2026 6:03 AM - StreetInsider
U.S. biopharma earnings: Eli Lilly (LLY), Pfizer (PFE) take the stage
August 1, 2026 10:00 AM - StreetInsider
Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Following Q2 Print
July 29, 2026 9:27 AM - StreetInsider
Gilead Sciences (GILD) PT Lowered to $145 at Barclays
July 29, 2026 5:19 AM - StreetInsider
Gilead Sciences (GILD) PT Lowered to $165 at Morgan Stanley
July 27, 2026 7:56 AM - StreetInsider
EU panel backs Gilead's Trodelvy plus Keytruda for breast cancer
July 24, 2026 6:26 AM - StreetInsider
CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
July 24, 2026 6:26 AM - BizWire
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
July 21, 2026 4:05 PM - BizWire
Gilead to present lenacapavir HIV trial data at AIDS 2026
July 21, 2026 10:00 AM - StreetInsider
Gilead and Merck HIV pill shows strong results in Phase 3 trials
July 21, 2026 10:00 AM - StreetInsider
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
July 21, 2026 10:00 AM - BizWire
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
July 21, 2026 10:00 AM - BizWire
Leerink Downgrades Gilead Sciences (GILD) to Market Perform
July 20, 2026 4:17 PM - StreetInsider
Form 4 GILEAD SCIENCES, INC. For: Jul 15 Filed by: Dickinson Andrew D
July 16, 2026 6:08 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Jul 15 Filed by: Mercier Johanna
July 16, 2026 4:55 PM - SEC Filing
Form 144 GILEAD SCIENCES, INC. Filed by: Mercier Johanna
July 15, 2026 4:13 PM - SEC Filing
Form 144 GILEAD SCIENCES, INC. Filed by: Dickinson Andrew D
July 15, 2026 4:11 PM - SEC Filing
Gilead Sciences (GILD) PT Lowered to $166 at Morgan Stanley
July 8, 2026 8:08 AM - StreetInsider
Gilead Sciences (GILD) PT Lowered to $120 at RBC Capital
July 7, 2026 7:55 AM - StreetInsider
Gilead Sciences (GILD) PT Lowered to $156 at Truist Securities
July 7, 2026 7:09 AM - StreetInsider
HSBC Upgrades Gilead Sciences (GILD) to Buy
July 6, 2026 1:35 AM - StreetInsider
Form 4 GILEAD SCIENCES, INC. For: Jul 01 Filed by: O'Day Daniel Patrick
July 2, 2026 4:14 PM - SEC Filing
FDA clears Gilead's Trodelvy for first-line metastatic TNBC
June 24, 2026 4:29 PM - StreetInsider
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
June 24, 2026 4:29 PM - BizWire
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
June 24, 2026 8:30 AM - StreetInsider
EU approves Gilead's Trodelvy for first-line metastatic TNBC
June 23, 2026 7:45 AM - StreetInsider
European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
June 23, 2026 7:45 AM - BizWire
Gilead Sciences (GILD) Reiterated at Overweight by Cantor Fitzgerald: Yeztugo Total TRx Down
June 22, 2026 7:39 AM - StreetInsider
Gilead Sciences (GILD) Reiterated at Overweight by Cantor Fitzgerald post CFO Chat
June 17, 2026 6:54 AM - StreetInsider
Form 4 GILEAD SCIENCES, INC. For: Jun 15 Filed by: Mercier Johanna
June 16, 2026 6:02 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Jun 15 Filed by: Dickinson Andrew D
June 16, 2026 5:53 PM - SEC Filing
Gilead Sciences (GILD) Reiterated at Overweight by Cantor Fitzgerald on FDA Approval
June 16, 2026 7:05 AM - StreetInsider
Gilead Sciences: FDA accepts GILEAD application for once-weekly oral HIV prevention pill
June 15, 2026 4:34 PM - StreetInsider
U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
June 15, 2026 4:34 PM - BizWire
Form 144 GILEAD SCIENCES, INC. Filed by: Dickinson Andrew D
June 15, 2026 4:31 PM - SEC Filing
Form 144 GILEAD SCIENCES, INC. Filed by: Mercier Johanna
June 15, 2026 4:09 PM - SEC Filing
Gilead donates remdesivir to Uganda for Ebola outbreak response
June 12, 2026 8:30 AM - StreetInsider
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
June 12, 2026 8:30 AM - BizWire
Form 4 GILEAD SCIENCES, INC. For: Jun 10 Filed by: Berger Dietmar
June 11, 2026 6:36 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Jun 10 Filed by: Cain Wettan Keeley M
June 11, 2026 6:34 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Jun 10 Filed by: Dickinson Andrew D
June 11, 2026 6:33 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Jun 10 Filed by: Mercier Johanna
June 11, 2026 6:31 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Jun 10 Filed by: O'Day Daniel Patrick
June 11, 2026 6:30 PM - SEC Filing
National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
June 11, 2026 8:30 AM - BizWire
Gilead Sciences (GILD) Reiterated at Overweight by Cantor Fitzgerald
June 9, 2026 6:54 AM - StreetInsider
Gilead and Merck announce successful HIV treatment trial results
June 8, 2026 4:35 PM - StreetInsider
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
June 8, 2026 4:35 PM - BizWire
Merck and Gilead discontinue lung cancer drug combination trial
June 8, 2026 4:30 PM - StreetInsider
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
June 8, 2026 4:30 PM - BizWire
RBC Capital: 'Where Does Gilead Sciences (GILD) Stand With In Vivo CAR-T?'
June 8, 2026 9:03 AM - StreetInsider
Full Article List
